Back to SGEN Stock Lookup
Pages: 1 2 »» Last Page

SGEN – FDA

Apr 8, 2014 09:02 AM Seattle Genetics Inc (SGEN) to Receive $6M ADCETRIS-Related Milestone
Jan 17, 2014 09:01 AM Seattle Genetics (SGEN) Reports Approval of ADCETRIS in Japan
Jan 13, 2014 12:33 PM Seattle Genetics (SGEN) Updates on FY14 ADCETRIS Milestones
Jan 8, 2014 09:08 AM Seattle Genetics (SGEN), AbbVie (ABBV) Expand ADC Collaboration
Dec 10, 2013 08:40 AM Seattle Genetics (SGEN) Presents Encouraging Data from ADCETRIS Phase 2 in DLBCL
Dec 9, 2013 11:26 AM SeattleGenetics (SGEN), Takeda Update on Survival Data from Two ADCETRIS Phase 2s
Oct 11, 2013 09:05 AM Seattle Genetics (SGEN) Updates on Several ADCETRIS Presentations Made at ISHL
Jun 26, 2013 07:37 AM Seattle Genetics (SGEN): Premature to Draw Link Between Adcetris and Pancreatitis - Jefferies
Jun 25, 2013 07:07 AM Seattle Genetics (SGEN) Enters Collaboration with Bayer; $20M Upfront, Worth Up to $500M Plus Royalties
Jun 21, 2013 09:06 AM Seattle Genetics (SGEN) to Present Data on Multiple ADCETRIS Trials
Jun 10, 2013 09:06 AM Seattle Genetics (SGEN) Initiates ADCETRIS Phase 1/2
Mar 18, 2013 09:08 AM Seattle Genetics (SGEN) Submits sBLA to FDA for Broader ADCETRIS Usage
Feb 1, 2013 02:07 PM Seattle Genetics' (SGEN) ADCETRIS Approved by Health Canada
Jan 24, 2013 09:02 AM Seattle Genetics (SGEN), Millennium Initiate ADCETRIS Phase III
Dec 11, 2012 07:06 AM Seattle Genetics (SGEN) Updates on Select ADC Programs by Roche's (RHHBY) Genentech
Dec 10, 2012 10:03 AM Seattle Genetics (SGEN) Updates on ADCETRIS in Relapsed HL
Nov 20, 2012 11:04 AM Seattle Genetics (SGEN) granted FDA orphan drug status for Mycois Fungoides
Oct 31, 2012 07:09 AM Seattle Genetics (SGEN) AADCETRIS® Receives EC Conditional Marketing Authorization
Oct 23, 2012 09:05 AM Seattle Genetics (SGEN) Expands ADC Collaboration w/ Abbott (ABT); Will Get $25M Upfront
Oct 17, 2012 09:09 AM Seattle Genetics (SGEN) Initiates ADCETRIS Phase II in New HL Patents Over 60
Oct 1, 2012 06:51 AM Millennium, Seattle Gen (SGEN) Updates on Sequential Therapy with Brentuximab Vedotin in Newly Diagnosed Patients with Systemic Anaplastic Large Cell Lymphoma
Sep 25, 2012 09:11 AM Seattle Genetics (SGEN) and Millennium Complete Enrollment for Phase III AETHERA Trial of ADCETRIS
Jul 20, 2012 10:46 AM Seattle Genetics (SGEN) Says Takeda Gets Positive ADCETRIS Recommendation from CHMP
Jun 14, 2012 07:06 AM Seattle Genetics (SGEN) Offers Updated Survival Data for Adcetris Trial, Says Median Overall Survival at 24 Months 65%
Jun 4, 2012 06:56 AM Seattle Genetics (SGEN) to Present Data from Several ADCETRIS Trials at ASCO
May 10, 2012 10:05 AM Seattle Genetics (SGEN) Updates on ADCETRIS Interim Phase II Data
Jan 13, 2012 06:47 AM Seattle Genetics (SGEN) Updates on Prescribing Info for ADCETRIS; Highlights PML Warning
Dec 12, 2011 01:03 PM Seattle Genetics (SGEN) Says ADCETRIS Has Clinically Meaningful Response, Safety Profile
Oct 25, 2011 09:04 AM Seattle Genetics (SGEN) Initiates ADCETRIS Phase II
Sep 26, 2011 07:05 AM Takeda, Seattle Genetics (SGEN) Applys for ADCETRIS MAA in Europe
Aug 23, 2011 09:39 AM Seattle Genetics (SGEN) Initiates Phase II Clinical Trial of ADCETRIS in CD30-Positive Non-Hodgkin Lymphoma
Aug 19, 2011 01:54 PM Seattle Genetics (SGEN) on the move as FDA has approved its lymphoma drug
Jul 15, 2011 10:03 AM Jefferies Boosts PT on Seattle Genetics (SGEN) Following FDA Panel Vote; Is Buyer on Weakness
Jul 14, 2011 05:05 PM Seattle Genetics (SGEN) Resumes Trading; Shares Down 9%
Jul 14, 2011 04:43 PM Seattle Genetics (SGEN) Set to Resume Trading at 5:05PM ET
Jul 14, 2011 04:35 PM Seattle Genetics (SGEN) Announces FDA Advisory Committee in Favor of Accelerated Approval of ADCETRIS
Jul 14, 2011 11:32 AM FDA Advisory Panel Votes 10-0 for Fast Approval of Seattle Genetics' Hodgkin Drug
Jul 12, 2011 03:33 PM Needham & Company maintains a 'Buy' on Seattle Genetics (SGEN); FDA Briefing Documents for the BLAs of ADCETRIS
Jul 12, 2011 08:10 AM Seattle Genetics (SGEN) FDA Briefing Documents Posted
Jun 27, 2011 07:23 AM Seattle Genetics (SGEN) to Receive Multi-Million Milestone Under ADCETRISTM Collaboration
Jun 16, 2011 09:02 AM Seattle Genetics (SGEN) Sets Date with FDA to Review Biologics License Applications for Brentuximab Vedotin
Jun 6, 2011 07:25 AM Jefferies Reiterates Bullish Stance On Seattle Genetics (SGEN) Related To Eventual Adcentris Label
May 27, 2011 09:06 AM Millennium, Seattle Gen (SGEN) to Present Brentuximab Vedotin Data
May 19, 2011 08:24 AM Needham & Co Highlights Seattle Genetics (SGEN), Pharmacyclics (PCYC), and Dendreon (DNDN) Ahead of ASCO
May 2, 2011 06:50 AM U.S. FDA Accepts Seattle Genetics' (SGEN) Brentuximab Vedotin BLA
Apr 6, 2011 08:48 AM Seattle Genetics (SGEN) Updates on SGN-35 in Hodgkin Lymphoma Patients
Mar 22, 2011 09:02 AM Seattle Genetics (SGEN), Abbott (ABT) Enter ADC Technology Collaboration
Mar 1, 2011 08:41 AM Seattle Genetics (SGEN), Millennium Initiate SGN-35 Phase I
Feb 28, 2011 06:52 AM Seattle Genetics (SGEN) Submits BLA for Brentuximab Vedotin to U.S. FDA
Dec 7, 2010 07:40 AM Seattle Genetics (SGEN) and Millennium Announce Positive Phase II SGN-35 Data in Patients with Relapsed ALCL
Pages: 1 2 »» Last Page

Back to SGEN Stock Lookup